Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin in Lower Limb Spasticity Post-Stroke or TBI
NCT03992404Phase 3Active, not recruiting
- Sponsor
- Merz
- Start
- Sep 2019
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
A Phase 3 trial of incobotulinumtoxinA in spasticity, sponsored by Merz. Started Sep 2019; status: active, not recruiting.
02
Drugs
incobotulinumtoxinA
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT03992404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992404.